Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- The Oppenheimer Rare & Orphan Disease Summit is taking place
Friday, May 21, 2021. Catalyst’s pre-recorded presentation will be available on May 21at 8:00 a.m. EDTand Catalyst’s management will host virtual 1x1 meetings following the presentation. The Jefferies Virtual Healthcare Conferenceis taking place June 1-4, 2021. Catalyst will present on Wednesday, June 2at 4 p.m. EDTand Catalyst’s management will host virtual 1x1 meetings throughout the day.
The presentation will be available on the Investor page of the company's website at www.catalystpharma.com promptly following the scheduled presentation time.
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the
David Schull Russo Partners(212) 845-4271 email@example.com Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.